Clinical trial NCT06375772: A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults
Official title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study Using the Rhinovirus Challenge Model to Investigate the Efficacy and Safety of 2-Deoxy-D-Glucose as Pre-exposure Prophylaxis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Acute Nasopharyngitis
Lead sponsor: G.ST Antivirals GmbH
Sponsor class: INDUSTRY
First posted: 2024-04-19
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: 2-DG-02 is a randomized, placebo-controlled, double-blind Phase 2 study to investigate the efficacy and safety of 2-Deoxy-D-Glucose as a pre-exposure prophylaxis using the rhinovirus challenge model in healthy study participants.

Detailed description: 2-DG-02 is a randomized, placebo-controlled, double-blind Phase 2 study using the rhinovirus challenge model in healthy study participants aged 18 to 64 years.

The primary objective is to confirm the efficacy of 2-DG compared to placebo for the prevention of rhinovirus-associated illness.

Secondary objectives are

* to evaluate the effect of 2-DG on the occurrence and course of rhinovirus infection
* to evaluate the effect of 2-DG on the severity of symptoms of rhinovirus infection
* to evaluate safety and tolerability of 2-DG administrated over 1 week in the presence of rhinovirus exposure
* to evaluate pharmacokinetics of 2-DG

  128 subjects, who have been pre-screened and found to be seronegative to rhinovirus type 39, are randomized 1:1 to either 2-DG (pre-exposure prophylaxis) or placebo the day prior to inoculation. Subjects receive 2-DG or placebo starting from the day prior to inoculation until 5 days post inoculation.

Interim safety and efficacy reviews are performed by a Safety Monitoring Committee.

Eligibility criteria: Inclusion Criteria:

* Healthy male or female subjects 18 to 64 (inclusive at screening) years of age.
* Women of childbearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception until end of study.
* Signed informed consent form prior to any study-related procedures.

Exclusion Criteria:

* Active smoker or history of smoking \> 5 pack years.
* Upper or lower respiratory tract infection or febrile illness
* Presence (at screening) of serum RV-39 neutralizing antibody titer at greater than one in four (1:4) dilution.
* Nasopharyngeal swab indicative for Influenza or SARS-CoV2 infection by rapid antigen test at baseline.
* Prior inoculation with a virus from the same virus family as the challenge virus.
* Any anatomic or neurologic abnormality impairing the gag reflex, or associated with an increased risk of aspiration, or any abnormality significantly altering the anatomy of the nose or nasopharynx in a substantial way that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge.
* Positive Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
* Any confirmed or suspected disease or condition associated with immune system impairment, including auto-immune diseases, asplenia or recurrent severe infections.
* Active allergic rhinitis or hay fever.
* Medical history or active asthma or chronic obstructive pulmonary disease (COPD) or any other pulmonary disease deemed by the investigator to increase the risk of participating in the study.
* Active nasal disease, e.g., nasal polyposis, significant septal deviation, chronic rhinosinusitis, etc.
* Frequent epistaxis or nasal sinus surgery within 3 months before baseline.
* Females: Pregnant, breast-feeding or intentions to become pregnant during the study.
* Evidence or history of drug or alcohol abuse.
* Positive test for drugs of abuse at screening or prior to study drug administration.
* Use of any prescribed or non-prescribed medication (except for contraceptives, paracetamol) within 1 week or less than 5 half-lives (whichever is longer) prior to the first administration of investigational product.
* Use of any over the counter cold prophylaxis products including nasal sprays, C-vitamins, zinc or Echinacea within 2 weeks prior to the first administration of investigational product.
* Participation in an investigational medical product, vaccine or device study within 3 months or 5 half-lives prior to the study period (whichever is longer), or more than 4 times in the past year.
* Hypersensitivity/allergy to any of the investigational product ingredients.
* Individuals with close contact to at risk patient group (infants less than 3 years, the extremely elderly \>80 years or infirm, pregnant women, patients with severe lung disease(e.g., asthma/cystic fibrosis (CF)/COPD), patients with primary or secondary immunodeficiencies or ongoing immunosuppressive therapy).
* Any clinically relevant abnormal history, physical finding, 12-lead safety ECG, vital signs, laboratory value at screening or any known factor that could interfere with the objectives of the trial or the safety of the volunteer. In the case of uncertain or questionable results, tests performed during screening may be repeated before inclusion to confirm eligibility or judged to be clinically irrelevant.

Primary outcomes:
measure: The difference in the rate of rhinovirus-associated illness between 2-DG and placebo
timeFrame: baseline until day 22
Secondary outcomes:
measure: Number of infected subjects
timeFrame: baseline, days 2-22 after start of dosing
measure: Difference in percent of infected subjects
timeFrame: baseline, days 2-22 after start of dosing
measure: Difference in percent of days virus positive
timeFrame: days 2-6
measure: Difference in peak nasal virus load
timeFrame: days 2-6
measure: Difference in AUC nasal virus load
timeFrame: days 2-6
measure: Difference in Total Jackson Symptom Score
timeFrame: days 2-6 after start of dosing
measure: Duration of illness
timeFrame: days 2-15 after start of dosing
measure: Difference in percent of days Jackson Symptom Score positive
timeFrame: days 2-6 after start of dosing
measure: Difference in Peak Jackson Symptom Score
timeFrame: days 2-6 after start of dosing
measure: Difference in peak total WURSS-21
timeFrame: days 2-6 after start of dosing
measure: Difference in AUC total WURSS-21
timeFrame: days 2-6 after start of dosing
measure: Occurrence of adverse events (AEs) and adverse drug-reactions (ADRs)
timeFrame: from screening (day -56) until end of study (day 22± 2) after start of dosing
measure: Biodistribution of multiple doses of 2-DG in plasma samples
timeFrame: baseline, days 6 and 22± 2 after start of dosing
measure: Biodistribution of multiple doses of 2-DG in nasal wash samples
timeFrame: baseline, days 2-6 and day 22± 2 after start of dosing
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Centre for Human Drug Research
Study officials:
affiliation: Centre for Human Drug Research
name: Ingrid de Visser-Kamerling, PhD
role: PRINCIPAL_INVESTIGATOR
References: